MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/jnci/djae295

Медицинская библиотека · Journal of the National Cancer Institute · 2025

Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.

Smith Randall J, Zollo Robert, Kalvapudi Sukumar, Vedire Yeshwanth, Pachimatla Akhil Goud, Petrucci Cara, Shaller Garrison, Washington Deschana, Rr Vethanayagam, Sass Stephanie N, Srinivasan Aravind, Kannisto Eric, Bawek Sawyer, Jain Prantesh, Rosario Spencer, Barbi Joseph, Yendamuri Sai

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Preclinical cancer studies ascribe promising anticancer properties to metformin. Yet, clinical findings vary, casting uncertainty on its therapeutic value for non-small cell lung cancer (NSCLC) patients. We hypothesized that metformin could benefit obese and overweight patients with NSCLC.

METHODS

We retrospectively analyzed 2 clinical cohorts and employed complementary mouse models to test our hypothesis. One cohort included NSCLC patients with overweight body mass index (≥25 kg/m2, n = 511) and nonoverweight body mass index (<25 kg/m2, n = 232) who underwent lobectomy, evaluating metformin's impact on clinical outcomes. Another cohort examined metformin's effect on progression-free survival after immune checkpoint inhibitors in overweight (n = 284) vs nonoverweight (n = 184) NSCLC patients. Metformin's effects on tumor progression, antitumor immunity, and immune checkpoint inhibitor response in obese and normal-weight mice were assessed with lung cancer models.

RESULTS

Metformin is associated with increased recurrence-free survival in overweight patients (hazard ratio [HR] = 0.47, 95% confidence interval [CI] = 0.24 to 0.94; P = .035) after lobectomy. It also corrected accelerated tumor growth in diet-induced obese mouse models in a lymphocyte-specific manner while reversing several mechanisms of immune suppression potentiated by obesity. Programmed cell death 1 blockade coupled with metformin was more effective at limiting tumor burden in obese mice and correlated with progression-free survival only in overweight patients on immunotherapy (HR = 0.60, 95% CI = 0.39 to 0.93; P = .024).

CONCLUSIONS

Metformin may improve lung cancer-specific clinical outcomes in obese and overweight lung cancer patients and enhance immunotherapy efficacy in this growing population. This work identifies obesity as a potential predictive biomarker of metformin's anticancer and immunotherapy-enhancing properties in lung cancer while shedding light on the underlying immunological phenomena.

Для цитирования: Smith Randall J, Zollo Robert, Kalvapudi Sukumar, Vedire Yeshwanth, Pachimatla Akhil Goud, Petrucci Cara, Shaller Garrison, Washington Deschana, Rr Vethanayagam, Sass Stephanie N, Srinivasan Aravind, Kannisto Eric, Bawek Sawyer, Jain Prantesh, Rosario Spencer, Barbi Joseph, Yendamuri Sai. Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.. Journal of the National Cancer Institute. 2025. DOI: 10.1093/jnci/djae295.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.